Codex DNA (TBIO): רווח למניה בשנים עשר החודשים האחרונים

Telesis Bio, Inc. (TBIO) production facilities are operating at maximum efficiency, maintaining equipment in ideal condition. The company is scaling sales of BioXp systems to capture the DNA pharmaceutical market. The fundamental TTM net income per share metric confirms the current trend, where the value -30.63 indicates the profitability status. Reliable logistics for reagents and electronics complete the cycle, eliminating laboratory downtime.

This indicator reflects the actual balance of market supply and demand, excluding speculative distortions. By analyzing the current trailing twelve-month EPS, an investor can observe the dynamics of specific return on equity. The metric is calculated as the sum of net income over the last four quarters divided by the current number of shares outstanding. For Telesis Bio, Inc. (TBIO), this figure is critical when scaling the delivery of BioXp systems. Growth in earnings per share would confirm the effectiveness of the expansion within the DNA synthesis sector.